The University of the Witwatersrand has been involved in a couple of COVID-19 vaccine trials. One of them is Oxford University’s AstraZeneca vaccine candidate, which announced its 70 per cent efficacy on average. Joining CNBC Africa to give an update on those vaccine trials is Shabir Madhi, Professor of Vaccinology at the University of Witwatersrand.
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent. Sign up here.